We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kingalf....if it breaks 10.85...next support is 8p
0 1 0
Compassionate use and accelerated development of any Covid-19 drug in patient trials that shows positive indications could be highly likely given the dire predictions of what's ahead. :-(
SAGE experts predict entire UK will be locked down by DECEMBER as they warn second wave will be deadlier than first with 500 deaths a day within weeks.
https://www.google.com/amp/s/www.dailymail.co.uk/news/article-8887775/amp/SAGE-experts-warn-second-wave-deadlier-first.html
What is your definition of imminent.
You've been banding it around for months
MM, you're not one of these scammers based in the Indian sub continent and have hired by some unscrupulous market makers to talk up the share so they can dump their position. Come clean, how long do you intend to go on for.
Lol....I've been here since 7p and have accumulated a sizeable chunk for the inevitable significant re-rate that is imminent....and any positive indications from the imminent Covid-19 patient trials will see Evgen's market cap rise from this current bargain £15m to several £100m and more...keep bashing King Canute, you haven't got a clue...ha ha ha :-)
According to the charts It went up to 15.5 p, as I have previously posted, this is definitely not a buy and hold share.
Why don't we now analyse your predictions on the share price over the last 6 months, I'm thinking the clueless dimwit crown sits better on your head.
Lol....you desperate numptie....just checked your posts here and the following post is the last time you mentioned the sp....ha ha ha ha ha....:-)
Kingalf
Posted in: EVG
Posts: 57
Price: 12.60
No Opinion
RE: Trial 08 Oct 2020 12:15
I could be wrong, but it looks like a breakout to the upside on the chart. Reinforced if it closes above 12.25 today.
Well my postings regarding the share price movements have certainly been spot on.
Here is another one for you, if 10.5p breaks, 8p will be the next support.
I might even go long there !!!!
Ps kingalf the Clueless ...;-)
No he wasn't, Company House confirmed 28/10/20 that his appointment was terminated 30/4/20, he was looked after by Evgen as he was allowed to accelerate his 4m plus share options the following month.
0
Accused of misinformation by the one who thinks he knows it all, for suggesting that SFX-01's randomized, double-blind, placebo-controlled Phase 2/3 Covid-19 patient trials could report early...ha ha ha...well here's an example of exactly what could happen if a therapeutic benefit is observed early during the trial...you couldn't a more similar example to SFX-01 and the imminent Covid-19 patient trials...Gla :-)
Covid-19 pneumonia drug candidate being prepared rapidly RedHill Biopharma collaborates with European and Canadian suppliers to ramp up production of opaganib for potential emergency use.
By Abigail Klein Leichman OCTOBER 28, 2020, 11:10 AM
RedHill Biopharma of Tel Aviv is collaborating with two pharmaceutical manufacturers in Europe and Canada to ramp up manufacturing of its drug candidate opaganib (Yeliva) or severe Covid-19 pneumonia.
The orally administered drug, which has anti-inflammatory and antiviral capabilities, could then meet potential demand for emergency use as the pandemic continues worldwide.
Under a compassionate use program, Covid-19 patients treated with opaganib in an Israeli hospital were discharged without requiring intubation and mechanical ventilation, whereas one-third of the matched case-control group required intubation and mechanical ventilation.
“Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes Covid-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue,” RedHill reports.
Opaganib is currently in global randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 and US Phase 2 studies in hospitalized patients with severe Covid-19 pneumonia requiring supplemental oxygen.
The US Phase 2 study is approaching completion of enrollment in eight sites, with initial results expected before the end of this year. The Phase 2/3 study is enrolling up to 270 patients across 15 study sites in six countries by year’s end.
RedHill is in discussions with US government agencies regarding rapid advancement of opaganib manufacturing toward potential emergency use applications.
Opaganib also has the potential to target multiple oncology, viral, inflammatory and gastrointestinal indications. It has FDA orphan drug status for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer.